
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Neurol. , 05 January 2023
Sec. Headache and Neurogenic Pain
Volume 13 - 2022 | https://doi.org/10.3389/fneur.2022.1123725
This article is a correction to:
No change in interictal C-reactive protein levels in individuals with episodic and chronic migraine: A case-control study and literature review
A corrigendum on
No change in interictal C-reactive protein levels in individuals with episodic and chronic migraine: A case-control study and literature review
by Park, C. G., Lee, S. H., and Chu, M. K. (2022). Front. Neurol. 13:1021065. doi: 10.3389/fneur.2022.1021065
In the published article, there was an error in the Funding statement. A National Research Foundation of Korea (NRF) grant was incorrectly omitted. The correct Funding statement appears below.
This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant No.: HV22C0106) and a National Research Foundation of Korea (NRF) grant from the Korean government (MSIT) (2022R1A2C1091767).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: biomarker, C-reactive protein, inflammation, migraine, headache
Citation: Park CG, Lee SH and Chu MK (2023) Corrigendum: No change in interictal C-reactive protein levels in individuals with episodic and chronic migraine: A case-control study and literature review. Front. Neurol. 13:1123725. doi: 10.3389/fneur.2022.1123725
Received: 14 December 2022; Accepted: 15 December 2022;
Published: 05 January 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Park, Lee and Chu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Min Kyung Chu, Y2h1bWtAeW9uc2VpLmFjLmty
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.